By Fineline Cube Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration to evaluate the combination of Zai Lab’s antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly ZL-1310) with Amgen’s Imdelltra (tarlatamab) for treating patients with extensive-stage small cell lung cancer (ES-SCLC).
Partnership Structure
| Aspect | Detail |
|---|---|
| Sponsor | Amgen Inc. |
| Study Type | Global Phase Ib clinical trial |
| Combination Therapy | Zocilurtatug pelitecan (ADC) + Tarlatamab (BiTE) |
| Target Population | ES-SCLC patients |
| Financial Terms | Undisclosed |
| Intellectual Property | Zai Lab retains full ownership of zocilurtatug pelitecan |
Drug Profiles & Mechanisms of Action
Zocilurtatug Pelitecan (Zoci)
- Drug Class: Antibody-drug conjugate (ADC)
- Target: Delta-like ligand 3 (DLL3)
- Clinical Performance:
- High response rates in heavily pretreated SCLC patients
- Significant intracranial activity
- Tolerable safety profile
- Development Stage: Phase I/II completed, advancing to combination studies
Tarlatamab (Imdelltra)
- Drug Class: DLL3-targeting bispecific T-cell engager (BiTE) therapy
- Regulatory Status: FDA-approved for adult ES-SCLC patients with disease progression on or after platinum-based chemotherapy
- Mechanism: Engages T-cells to target and eliminate DLL3-expressing tumor cells
Scientific Rationale for Combination
- Dual DLL3 Targeting: Both agents target DLL3 through complementary mechanisms—ADC delivers cytotoxic payload directly to tumor cells while BiTE recruits immune system for tumor cell killing
- Potential Synergy: Combination may enhance anti-tumor efficacy through simultaneous direct cytotoxicity and immune-mediated tumor clearance
- Addressing Unmet Need: ES-SCLC remains challenging to treat with limited therapeutic options post-platinum failure
Strategic Implications
For Zai Lab
- Global Validation: Partnership with major biopharma validates zoci’s clinical potential
- Resource Optimization: Leverages Amgen’s global clinical development infrastructure
- Asset Retention: Maintains full ownership while gaining access to combination development expertise
For Amgen
- Portfolio Expansion: Enhances Imdelltra’s utility through rational combination strategy
- Competitive Positioning: Strengthens position in competitive ES-SCLC market
- Innovation Pipeline: Access to promising ADC technology without upfront acquisition costs
Market Context
- ES-SCLC Landscape: Limited treatment options create significant commercial opportunity for effective therapies
- DLL3 Targeting: Emerging as key therapeutic target in SCLC with multiple approaches in development
- Combination Trend: Reflects broader industry shift toward rational combination therapies to improve outcomes
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development plans, partnership benefits, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech